A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation
- 12 September 2012
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 18 (32), 5131-5140
- https://doi.org/10.2174/138161212802884681
Abstract
Whilst the delta-9-tetrahydrocannabinol (THC) component of cannabis can induce transient psychotic experiences, this critical review found that recent evidence suggests another component, cannabidiol (CBD), may actually be antipsychotic. This Recommendation is of an article referenced in an F1000Prime Report also written by Suzanne Gage, Stanley Zammit and Matthew Hickman.Keywords
This publication has 47 references indexed in Scilit:
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophreniaTranslational Psychiatry, 2012
- Modulation of Auditory and Visual Processing by Delta-9-Tetrahydrocannabinol and Cannabidiol: an fMRI StudyNeuropsychopharmacology, 2011
- Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesisCell Communication and Signaling, 2010
- Antidepressant‐like effects of cannabidiol in mice: possible involvement of 5‐HT1AreceptorsBritish Journal of Pharmacology, 2010
- Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and PsychopathologyNeuropsychopharmacology, 2009
- The Hippocampus and Nucleus Accumbens as Potential Therapeutic Targets for Neurosurgical Intervention in SchizophreniaStereotactic and Functional Neurosurgery, 2009
- Modulation of Excitatory Synaptic Transmission by Δ9-Tetrahydrocannabinol Switches from Agonist to Antagonist Depending on Firing RatePublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2008
- 5‐HT1A receptors are involved in the cannabidiol‐induced attenuation of behavioural and cardiovascular responses to acute restraint stress in ratsBritish Journal of Pharmacology, 2008
- The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarinBritish Journal of Pharmacology, 2008
- Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitroBritish Journal of Pharmacology, 2007